{"entity":{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","aka":[],"tldr":"Gemelli is Rome's Catholic university hospital and a leader in gynaecologic oncology.","summary":"Policlinico Universitario A. Gemelli is Rome's Catholic university hospital and a leader in gynaecologic oncology, ranked twenty-ninth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its gynaecologic oncology programme, associated with Giovanni Scambia, sits alongside radiotherapy and gastrointestinal surgery, with Anna Fagotti, Vincenzo Valentini and Giampaolo Tortora among the people OnCo lists, and it plays a role in ovarian, cervical and endometrial cancer trials. OnCo links it to the KEYNOTE-A18 cervical cancer paper and to PAOLA-1 in ovarian cancer, and to the European Society of Gynaecological Oncology and Fondazione AIRC. How to extend PARP inhibitor benefit beyond HRD-positive ovarian tumours is the question its trial work keeps returning to. Its gynaecologic programme is the reason to read this page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.policlinicogemelli.it"}],"tags":[],"related":[],"cancers":["ovarian","cervical","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["giampaolo-tortora","anna-fagotti","giovanni-scambia","vincenzo-valentini","daniele-piacentini"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rome","country":"IT","lat":41.933,"lng":12.428,"institutionType":"university","website":"https://www.policlinicogemelli.it","newsweekOncology2026":29,"programs":["Gynaecologic oncology"]},"route":"/institutions/gemelli/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"person":[{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/"},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","route":"/people/daniele-piacentini/"},{"id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","route":"/people/giampaolo-tortora/"},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/"},{"id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","route":"/people/vincenzo-valentini/"}],"paper":[{"id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/"},{"id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/"},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/"}],"institution":[{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/"},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/"},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/"}]}}